Marathon Asset Management (UK)’s Royalty Pharma RPRX Stock Holding History

Marathon Asset Management (UK)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.2M	Buy	440,928 +52,702	+14%	+$2.31M	0.81%	41
2025 Q4	$15M	Sell	388,226 -37,846	-9%	-$1.44M	0.58%	48
2025 Q3	$15M	Sell	426,072 -153,549	-26%	-$5.56M	0.55%	46
2025 Q2	$20.9M	Sell	579,621 -66,625	-10%	-$2.21M	0.67%	45
2025 Q1	$20.1M	Sell	646,246 -68,924	-10%	-$2.18M	0.61%	46
2024 Q4	$18.2M	Sell	715,170 -46,981	-6%	-$1.25M	0.51%	53
2024 Q3	$21.6M	Buy	762,151 +18,424	+2%	+$510K	0.6%	51
2024 Q2	$19.6M	Sell	743,727 -48,680	-6%	-$1.35M	0.61%	55
2024 Q1	$24.1M	Sell	792,407 -60,011	-7%	-$1.77M	0.64%	55
2023 Q4	$23.9M	Buy	852,418 +86,585	+11%	+$2.38M	0.67%	58
2023 Q3	$20.8M	Sell	765,833 -37,334	-5%	-$1.11M	0.65%	59
2023 Q2	$24.7M	Sell	803,167 -90,025	-10%	-$3.05M	0.69%	56
2023 Q1	$32.2M	Sell	893,192 -138,077	-13%	-$5.12M	0.9%	46
2022 Q4	$40.8M	Sell	1,031,269 -42,476	-4%	-$1.77M	1.1%	33
2022 Q3	$43.1M	Sell	1,073,745 -891,591	-45%	-$38.1M	1.29%	30
2022 Q2	$82.6M	Sell	1,965,336 -111,392	-5%	-$4.57M	1.38%	24
2022 Q1	$80.9M	Sell	2,076,728 -165,602	-7%	-$6.5M	1.1%	39
2021 Q4	$89.4M	Buy	+2,242,330	New	+$87.1M	1.11%	39

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Marathon Asset Management (UK)'s RPRX Position: Q1 2026 in Review

Marathon Asset Management (UK) increased its Royalty Pharma (RPRX) stake by 14% in Q1 2026, buying an estimated $2.31M and bringing the position to 440,928 shares worth $21.2M. The position accounts for 0.81% of the portfolio, ranked #41.

Marathon Asset Management (UK) first reported a position in RPRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $89.4M in Q4 2021. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Marathon Asset Management (UK) held 440,928 shares of Royalty Pharma worth $21.2M as of Q1 2026.
Marathon Asset Management (UK) bought 52,702 Royalty Pharma shares in Q1 2026, an estimated $2.31M.
Royalty Pharma made up 0.81% of Marathon Asset Management (UK)'s portfolio in Q1 2026, its #41 holding.
Marathon Asset Management (UK) first reported a position in Royalty Pharma in Q4 2021 and has held it in 18 quarters since.
Marathon Asset Management (UK)'s Royalty Pharma position peaked at $89.4M in Q4 2021.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Marathon Asset Management (UK)'s 13F filing for Q1 2026, filed 24 Apr 2026.